Pancreatic Cancer Research

ResearcherJiangsu Province HospitalActive in the last 2 years

Zekuan Xu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5179-4128; OpenAlex author ID A5068744621. Sources: OpenAlex.

Their work

Papers
22 (first author 0, last author 13)
Trials
0
Grants
0
Labs led
1
Collaborators
44
Papers, trials and grants by year

2011: 4 papers · 2012: 1 paper · 2013: 2 papers · 2014: 9 papers · 2015: 2 papers · 2016: 2 papers · 2017: none · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: none · 2024: none · 2025: 1 paper · 2026: 1 paper

Papers 22

  1. Editorial Expression of Concern: SATB1 Promotes Pancreatic Cancer Growth and Invasion Depending on MYC Activation. Last author DOI 10.1007/s10620-026-10211-5↗
  2. Editorial expression of concern: Yin Yang-1 suppresses invasion and metastasis of pancreatic ductal adenocarcinoma by downregulating MMP10 in a MUC4/ErbB2/p38/… Co-author DOI 10.1186/s12943-025-02326-6↗
  3. The role of the AMOP domain in MUC4/Y-promoted tumour angiogenesis and metastasis in pancreatic cancer. Last author DOI 10.1186/s13046-016-0369-0↗
  4. Yin Yang-1 increases apoptosis through Bax activation in pancreatic cancer cells. Last author DOI 10.18632/oncotarget.8654↗
  5. SATB1 Promotes Pancreatic Cancer Growth and Invasion Depending on MYC Activation. Last author DOI 10.1007/s10620-015-3759-9↗
  6. MUC4-promoted neural invasion is mediated by the axon guidance factor Netrin-1 in PDAC. Last author DOI 10.18632/oncotarget.5668↗
  7. MUC4-induced nuclear translocation of β-catenin: a novel mechanism for growth, metastasis and angiogenesis in pancreatic cancer. Last author DOI 10.1016/j.canlet.2013.12.021↗
  8. Elevation of MMP-9 and IDO induced by pancreatic cancer cells mediates natural killer cell dysfunction. Co-author DOI 10.1186/1471-2407-14-738↗
  9. Yin Yang-1 suppresses invasion and metastasis of pancreatic ductal adenocarcinoma by downregulating MMP10 in a MUC4/ErbB2/p38/MEF2C-dependent mechanism. Co-author DOI 10.1186/1476-4598-13-130↗
  10. Specific-detection of clinical samples, systematic functional investigations, and transcriptome analysis reveals that splice variant MUC4/Y contributes to the … Last author DOI 10.1186/s12967-014-0309-8↗
  11. HERG1 functions as an oncogene in pancreatic cancer and is downregulated by miR-96. Last author DOI 10.18632/oncotarget.2200↗
  12. Pancreatic cancer counterattack: MUC4 mediates Fas-independent apoptosis of antigen-specific cytotoxic T lymphocyte. Last author DOI 10.3892/or.2014.3016↗
  13. Upregulation of the splice variant MUC4/Y in the pancreatic cancer cell line MIA PaCa-2 potentiates proliferation and suppresses apoptosis: new insight into th… Last author DOI 10.3892/or.2014.3113↗
  14. PP2A inhibitors suppress migration and growth of PANC-1 pancreatic cancer cells through inhibition on the Wnt/β-catenin pathway by phosphorylation and degradat… Co-author DOI 10.3892/or.2014.3266↗
  15. [Down-regulated expression of PP2A catalytic subunit in pancreatic cancer cells promotes cell growth]. Last author PMID 24721345↗
  16. Comprehensive analysis of the percentage of surface receptors and cytotoxic granules positive natural killer cells in patients with pancreatic cancer, gastric … Co-author DOI 10.1186/1479-5876-11-262↗
  17. CEACAM6 induces epithelial-mesenchymal transition and mediates invasion and metastasis in pancreatic cancer. Co-author DOI 10.3892/ijo.2013.2015↗
  18. Association of increased DNA methyltransferase expression with carcinogenesis and poor prognosis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s12094-012-0770-x↗
  19. The increase in the expression and hypomethylation of MUC4 gene with the progression of pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s12032-010-9683-0↗
  20. PP2A inhibitors induce apoptosis in pancreatic cancer cell line PANC-1 through persistent phosphorylation of IKKα and sustained activation of the NF-κB pathway. Last author DOI 10.1016/j.canlet.2011.02.009↗
  21. Growth of the pancreatic cancer cell line PANC-1 is inhibited by protein phosphatase 2A inhibitors through overactivation of the c-Jun N-terminal kinase pathwa… Last author DOI 10.1016/j.ejca.2011.08.014↗
  22. Galectin-1 secreted by activated stellate cells in pancreatic ductal adenocarcinoma stroma promotes proliferation and invasion of pancreatic cancer cells: an i… Co-author DOI 10.1097/mpa.0b013e318217945e↗

Closest collaborators

The 25 strongest of 44 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yi Miao · 4 shared papers, 2013–2026 · strength 0.61
  2. Zheng Chen · 7 shared papers, 2011–2026 · strength 0.56
  3. Jie Tang · 7 shared papers, 2014–2025 · strength 0.47
  4. Wentao Gao · 8 shared papers, 2011–2025 · strength 0.44
  5. Kun-Ling Xie · 6 shared papers, 2014–2025 · strength 0.42
  6. Kuirong Jiang · 7 shared papers, 2011–2025 · strength 0.41
  7. Junli Wu · 7 shared papers, 2011–2025 · strength 0.40
  8. Yi Miao · 11 shared papers, 2011–2016 · strength 0.40
  9. Yunpeng Peng · 5 shared papers, 2013–2025 · strength 0.38
  10. Zhuyin Qian · 5 shared papers, 2011–2025 · strength 0.33
  11. Jingjing Zhang · 4 shared papers, 2011–2025 · strength 0.32
  12. Jingjing Zhang · 8 shared papers, 2011–2016 · strength 0.31
  13. Zheng Li · 2 shared papers, 2014–2025 · strength 0.25
  14. Xiaofei Zhi · 5 shared papers, 2014–2016 · strength 0.22
  15. Yi Zhu · 5 shared papers, 2011–2014 · strength 0.18
  16. Wěi Li · 2 shared papers, 2014–2015 · strength 0.10
  17. Linjun Wang · 2 shared papers, 2015–2016 · strength 0.10
  18. Jishu Wei · 3 shared papers, 2011–2014 · strength 0.09
  19. Min Tao · 3 shared papers, 2011–2014 · strength 0.09
  20. Daoming Li · 2 shared papers, 2011–2014 · strength 0.07
  21. Chuang Yang · 1 shared paper, 2016 · strength 0.06
  22. Kuirong Jiang · 1 shared paper, 2016 · strength 0.06
  23. Zipeng Lu · 2 shared papers, 2011–2014 · strength 0.06
  24. Qiang Li · 2 shared papers, 2011–2013 · strength 0.05
  25. Yong An · 2 shared papers, 2011–2013 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.